Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.65 |
| ▸ | MGLL | Q99685 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447074 | 0.85 | MGLL (0.67) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL29448588 | 0.85 | KMT2A (0.77) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL14640729 | 0.84 | MEN1 (0.56) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL6212608 | 0.84 | HSD11B1 (0.74) | HSD11B1MGLLPOLBALDH1A1 | |
| SCHEMBL7330630 | 0.83 | CPB1 (0.63) | HSD11B1MGLLKMT2AMEN1ALDH1A1 | |
| SCHEMBL10112201 | 0.83 | HSD11B1 (0.60) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL18321777 | 0.83 | MGLL (0.60) | HSD11B1MGLLKMT2AMEN1ALDH1A1 | |
| SCHEMBL13944269 | 0.81 | MEN1 (0.54) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL7246949 | 0.81 | POLB (0.78) | HSD11B1MGLLKMT2AMEN1POLB | |
| SCHEMBL9249863 | 0.81 | SLC18A3 (0.56) | HSD11B1MGLLKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2022-03-17 | — | — | US | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | disclosed |
| EP-0110435-B1 | NOVEL ((BIS(ARYL)METHYLENE)-1-PIPERIDINYL)ALKYL-PYRIMIDINONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-04 | — | — | EP | disclosed |
| US-4581171-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1986-04-08 | — | — | US | disclosed |
| US-4533665-A | SEROTONIN ANTAGONIST | JANSSEN PHARMACEUTICA (BE) | 1985-08-06 | — | — | US | disclosed |
| US-4485107-A | SEDATIVES, MUSCLE RELAXANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-11-27 | — | — | US | disclosed |
| EP-0110435-A1 | Novel ((bis(aryl)methylene)-1-piperidinyl)alkyl-pyrimidinones | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-06-13 | — | — | EP | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HSD11B1 2469/4885MGLL 1407/4885KMT2A 3292/4885 |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | HSD11B1 370/4885MGLL 396/4885KMT2A 2164/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | HSD11B1 370/4885MGLL 396/4885KMT2A 2164/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | HSD11B1 603/4885MGLL 825/4885KMT2A 2330/4885 |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | FASN, CES1, FADS2 | HSD11B1 363/4885MGLL 346/4885KMT2A 2257/4885 |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | HSD11B1 370/4885MGLL 396/4885KMT2A 2164/4885 |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | HSD11B1 370/4885MGLL 396/4885KMT2A 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.